3 Active Ingredients and Custom Manufacturing Company, Excipients and Nutrition Ingredients Maker and Portable Molecular Testing Firm Stocks With a Strong Future Roadmap: Neuland Laboratories, Sudeep Pharma and Molbio Diagnostics
- October 26, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Neuland Laboratories, Sudeep Pharma and Molbio Diagnostics: ROE of 14.2% to 19.6% and FY22 to FY26 revenue CAGR of 16.8% to 21.1%. Prices as of 23 Oct 2026.
Quick Answer
The three API, excipient and Truenat diagnostics stocks to watch are Neuland Laboratories, Sudeep Pharma and Molbio Diagnostics. Their return on equity ranges from 14.2% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 16.8% to 21.1%. Sudeep Pharma has the highest return on equity at 19.6%, while Neuland Laboratories has the fastest revenue growth at 21.1% a year. Prices are based on the 23 October 2026 close, and this article is educational, not investment advice.
API, excipient and Truenat diagnostics stocks give investors a way to track businesses that sit close to everyday demand in India. Neuland Laboratories, Sudeep Pharma and Molbio Diagnostics cover an active ingredients and custom manufacturing company, an excipients and nutrition ingredients maker and a portable molecular testing firm.
This list covers three API, excipient and Truenat diagnostics stocks with complete current figures: Neuland Laboratories, Sudeep Pharma and Molbio Diagnostics. Every figure comes from the latest reported financials and the 23 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are API, Excipient and Truenat Diagnostics Stocks?
API, excipient and Truenat diagnostics stocks are listed healthcare companies that make active ingredients, excipients and portable disease tests. Their earnings depend on global orders, custom projects, approvals and testing demand.
API, Excipient and Truenat Diagnostics Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Neuland Laboratories | 18,865 | 24,665 | 49.5 | 36.0 | 19.4 | 0.16 |
| Sudeep Pharma | 966.2 | 11,352 | 61.8 | 35.1 | 19.6 | 0.17 |
| Molbio Diagnostics | 1,239.1 | 16,605 | 101.2 | 59.6 | 14.2 | 0.38 |
On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing API, excipient and Truenat diagnostics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do API, Excipient and Truenat Diagnostics Stocks Have a Strong Roadmap in India?
API, excipient and Truenat diagnostics stocks have a strong roadmap in India because global buyers add dependable ingredient suppliers and portable testing widens access to diagnosis.
- Custom projects. Global drug makers outsource complex molecules.
- Excipients. Every tablet and capsule needs inactive ingredients.
- Point of care tests. Portable devices reach remote areas.
Why Neuland Laboratories Features Among These API, Excipient and Truenat Diagnostics Stocks
Among the API, excipient and Truenat diagnostics stocks on this list, Neuland Laboratories, based in Hyderabad, makes active pharmaceutical ingredients for generic drugs and runs a custom manufacturing business that supplies innovator companies.
The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0.
Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%.
Roadmap: The company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.
What to watch: Custom manufacturing revenue can move between quarters, so review the full-year trend.
Why Sudeep Pharma Features Among These API, Excipient and Truenat Diagnostics Stocks
Among the ingredient maker company shares on this list, Sudeep Pharma makes pharmaceutical excipients, food ingredients and nutritional additives such as minerals and fortification products for domestic and global customers.
Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%.
In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1.
Roadmap: Excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
What to watch: Check capacity expansion progress and export revenue growth.
Why Molbio Diagnostics Features Among These API, Excipient and Truenat Diagnostics Stocks
Among the three companies on this list, Molbio Diagnostics, based in Goa, develops the Truenat platform, a portable molecular diagnostics system that delivers lab-grade PCR results at the point of care, with strong use in tuberculosis testing.
Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%.
The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6.
Roadmap: Its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What to watch: Order timing from public health programmes can be lumpy, so look at annual rather than single-quarter trends.
Neuland Laboratories vs Sudeep Pharma vs Molbio Diagnostics on Key Financials
The table below sets the three API, excipient and Truenat diagnostics stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Neuland Laboratories | 953 | 2,053 | 21.1% | 364 | 17.7% |
| Sudeep Pharma | 350 | 671 | 17.6% | 174 | 26.0% |
| Molbio Diagnostics | 782 | 1,455 | 16.8% | 164 | 11.3% |
Sudeep Pharma posts the highest return on equity in this group at 19.6%. Neuland Laboratories combines the largest FY26 revenue at Rs 2,053 crore with the fastest revenue growth, a 21.1% compound annual rate. A useful habit with API, excipient and Truenat diagnostics stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in API, Excipient and Truenat Diagnostics Stocks
Every theme carries risks that deserve a check before any decision. For these API, excipient and Truenat diagnostics stocks, the main points are:
- Regulatory checks. Plant inspections can affect approvals.
- Order timing. Large contracts can shift between periods.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter API, excipient and Truenat diagnostics stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on API, Excipient and Truenat Diagnostics Stocks
API, excipient and Truenat diagnostics stocks work best when investors track growth, valuation and return on equity side by side. Neuland Laboratories, Sudeep Pharma and Molbio Diagnostics each have a clear plan to grow. Based on the 23 October 2026 close, Neuland Laboratories trades at Rs 18,865, Sudeep Pharma at Rs 966.2 and Molbio Diagnostics at Rs 1,239.1.
Download the Univest iOS App or Univest Android App to track API, excipient and Truenat diagnostics stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are API, excipient and Truenat diagnostics stocks?
Ans. API, excipient and Truenat diagnostics stocks are listed healthcare companies that make active ingredients, excipients and portable disease tests. Their earnings depend on global orders, custom projects, approvals and testing demand. This list looks at three of them, Neuland Laboratories, Sudeep Pharma and Molbio Diagnostics, using reported FY22 to FY26 financials and the 23 October 2026 closing prices.
Which API, excipient and Truenat diagnostics stocks are covered in this list?
Ans. This list covers Neuland Laboratories, Sudeep Pharma and Molbio Diagnostics. Based on the 23 October 2026 close, Neuland Laboratories traded at Rs 18,865, Sudeep Pharma at Rs 966.2 and Molbio Diagnostics at Rs 1,239.1. Their return on equity ranges from 14.2% to 19.6%, and their revenue compound annual growth from FY22 to FY26 ranges from 16.8% to 21.1%.
Why do API, excipient and Truenat diagnostics stocks have a strong future roadmap in India?
Ans. API, excipient and Truenat diagnostics stocks have a strong roadmap in India because global buyers add dependable ingredient suppliers and portable testing widens access to diagnosis. The main drivers are as follows. Custom projects. Global drug makers outsource complex molecules. Excipients. Every tablet and capsule needs inactive ingredients. Point of care tests. Portable devices reach remote areas. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Neuland Laboratories performed financially?
Ans. Revenue rose from Rs 953 crore in FY22 to Rs 2,053 crore in FY26, a compound annual growth rate of 21.1%. Net profit grew from Rs 63.8 crore in FY22 to Rs 364 crore in FY26, which works out to a compound annual growth rate of 54.5%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.16 and a market capitalisation of Rs 24,665 crore. The stock trades at a P/E of 49.5, above the industry P/E of 36.0. Looking ahead, the company is moving up the value chain by growing custom manufacturing, which carries longer contracts and better margins than commodity generic ingredients. A strong order book for development-stage molecules gives visibility on multi-year volumes.
How has Sudeep Pharma performed financially?
Ans. Revenue rose from Rs 350 crore in FY22 to Rs 671 crore in FY26, a compound annual growth rate of 17.6%. Net profit grew from Rs 50.2 crore in FY22 to Rs 174 crore in FY26, which works out to a compound annual growth rate of 36.5%. In the June 2026 quarter, revenue grew 25.9% year on year to Rs 164 crore, while net profit rose 29.8% to Rs 40.6 crore. The company has a return on equity of 19.6%, a debt to equity ratio of 0.17 and a market capitalisation of Rs 11,352 crore. The stock trades at a P/E of 61.8, above the industry P/E of 35.1. Looking ahead, excipients and nutritional ingredients are in steady demand from pharma and food customers, and the company is a leading supplier in its niche. Capacity additions and regulatory approvals open up new export markets.
How has Molbio Diagnostics performed financially?
Ans. Revenue rose from Rs 782 crore in FY22 to Rs 1,455 crore in FY26, a compound annual growth rate of 16.8%. Net profit grew from Rs 83.5 crore in FY24 to Rs 164 crore in FY26, which works out to a compound annual growth rate of 40.2%. The company has a return on equity of 14.2%, a debt to equity ratio of 0.38 and a market capitalisation of Rs 16,605 crore. The stock trades at a P/E of 101.2, above the industry P/E of 59.6. Looking ahead, its roadmap centres on widening the Truenat test menu beyond TB, pushing into more countries through government and donor programmes, and building recurring revenue from test chips and consumables on top of the installed analyser base.
What risks should investors check before buying API, excipient and Truenat diagnostics stocks?
Ans. Investors should check a few risks before buying API, excipient and Truenat diagnostics stocks. Regulatory checks. Plant inspections can affect approvals. Order timing. Large contracts can shift between periods. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of API, excipient and Truenat diagnostics stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 23 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.